LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "resectable nsclc" as a keyword



Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC

Sign Up to like & get
recommendations! Published in 2024 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2024.1285

Abstract: Key Points Question Is administration of programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors both before and after surgery (neoadjuvant-adjuvant treatment) associated with better outcomes than administration of the therapy solely… read more here.

Keywords: treatment; neoadjuvant adjuvant; patients resectable; neoadjuvant inhibitors ... See more keywords

Peri-operative adjuvant treatment for potential resectable NSCLC

Sign Up to like & get
recommendations! Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz353

Abstract: Abstract Adjuvant chemotherapy is the standard treatment for resected stage 2-3 NSCLC since 2006. It increased OS by 5% at 5 years. There is a huge medical need to improve the long-term survival for these… read more here.

Keywords: peri operative; trial; treatment; operative adjuvant ... See more keywords

Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-ct081

Abstract: Background: In the global, randomized phase 3 CheckMate 816 study (NCT02998528), neoadjuvant NIVO + chemo demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and pathologic complete response (pCR) vs chemo in pts… read more here.

Keywords: resectable nsclc; nivo chemo; chemo chemo; checkmate 816 ... See more keywords

Abstract 5816: TCR clonal tracking maps tumor-draining lymph nodes as reservoirs fueling neoadjuvant PD-1 blockade in resectable NSCLC

Sign Up to like & get
recommendations! Published in 2025 at "Cancer Research"

DOI: 10.1158/1538-7445.am2025-5816

Abstract: PD-1 blockade with platinum chemotherapy (chemo/IO) has transformed treatment for resectable non-small cell lung cancer (NSCLC). However, gaps in understanding the adaptive T cell response impede progress, resulting in a lack of predictive biomarkers and… read more here.

Keywords: tumor draining; cell; tumor; draining lymph ... See more keywords

Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials

Sign Up to like & get
recommendations! Published in 2024 at "BMC Cancer"

DOI: 10.1186/s12885-024-13311-5

Abstract: The efficacy of neoadjuvant immunotherapy in resectable non-small-cell lung cancer (NSCLC) is controversial. The aim of this study is to explore the efficacy of additional PD-1/PD-L1 inhibitors in the neoadjuvant treatment of resctable NSCLC. Data… read more here.

Keywords: efficacy neoadjuvant; analysis; tps; efficacy ... See more keywords

Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC

Sign Up to like & get
recommendations! Published in 2024 at "BMC Pulmonary Medicine"

DOI: 10.1186/s12890-024-03041-6

Abstract: Background The incidence of checkpoint inhibitor-associated pneumonitis (CIP) in advanced non-small cell lung cancer (NSCLC) has been substantiated through large-scale clinical trials or real-world studies. However, reports on CIP incidence within the context of neoadjuvant… read more here.

Keywords: cip; neoadjuvant immunochemotherapy; resectable nsclc; risk factors ... See more keywords

Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.8_suppl.99

Abstract: 99 Background: Targeting PD-L1/PD-1 to activate anti-tumor immunity is associated with improved response and survival compared to chemo in NSCLC pts. We present a preliminary analysis of the clinical efficacy, safety and peripheral blood (PB)… read more here.

Keywords: mpr; response; immunophenotyping; atezolizumab ... See more keywords

Identification of Resectable N2 in NSCLC: A Single Center Experience and Review of the SEER Database

Sign Up to like & get
recommendations! Published in 2021 at "Frontiers in Oncology"

DOI: 10.3389/fonc.2021.647546

Abstract: Background Non-small cell lung carcinoma (NSCLC) with ipsilateral and/or subcarinal mediastinal lymphatic spread (N2) is a heterogeneous disease. The role of surgical resection in patients with N2 NSCLC remains controversial and no survival-based definition of… read more here.

Keywords: identification resectable; risk; seer; seer database ... See more keywords